FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2761488148> ?p ?o ?g. }

• W2761488148 endingPage "200" @default.
• W2761488148 startingPage "194" @default.
• W2761488148 abstract "Myelofibrosis (MF) is a severe disease, with decreased life expectancy and heavy symptom burden. Ruxolitinib is the only approved pharmacotherapy for the treatment of MF patients. In Belgium, ruxolitinib is only reimbursed for MF patients with splenomegaly for whom the disease is categorized as intermediate-2 or high risk. The improvement of symptoms without spleen volume reduction is not considered sufficient to continue treatment. The aim of this manuscript is to provide guidance for the safe and effective administration of ruxolitinib, considering the particularities of the Belgian reimbursement criteria.Our recommendations are based on a consensus reached during two meetings, where available data and observations derived from clinical experience were discussed.We recommend changing the current Belgian reimbursement conditions to include the evaluation of disease-related symptoms along with splenomegaly to decide whether ruxolitinib treatment should be continued or not. Indeed, the decrease in disease-related symptoms seems to be an equally important parameter as the decrease in splenic volume in the evaluation of the response to ruxolitinib. We also advocate for the treatment with ruxolitinib of MF patients in lower-risk categories with severe disease-related symptoms, as this drug could greatly improve their quality of life. Optimization of the ruxolitinib dose is recommended to avoid an unnecessary decrease in platelet count or hemoglobin that may jeopardize treatment continuation.With the aim to optimize the treatment of MF patients, the Belgian regulation for ruxolitinib should be revised in terms of reimbursement criteria, dose titration, stopping rules, and patient follow-up." @default.
• W2761488148 created "2017-10-20" @default.
• W2761488148 creator A5036582191 @default.
• W2761488148 creator A5037134717 @default.
• W2761488148 creator A5057335043 @default.
• W2761488148 creator A5091536542 @default.
• W2761488148 date "2017-10-12" @default.
• W2761488148 modified "2023-09-28" @default.
• W2761488148 title "Recommendations on the use of ruxolitinib for the treatment of myelofibrosis" @default.
• W2761488148 cites W1503482160 @default.
• W2761488148 cites W1766283728 @default.
• W2761488148 cites W1924834505 @default.
• W2761488148 cites W1956410366 @default.
• W2761488148 cites W1995162107 @default.
• W2761488148 cites W2008799537 @default.
• W2761488148 cites W2014091629 @default.
• W2761488148 cites W2016406604 @default.
• W2761488148 cites W2018254868 @default.
• W2761488148 cites W2024401882 @default.
• W2761488148 cites W2025592929 @default.
• W2761488148 cites W2028961479 @default.
• W2761488148 cites W2043993681 @default.
• W2761488148 cites W2052451894 @default.
• W2761488148 cites W2079188240 @default.
• W2761488148 cites W2080444865 @default.
• W2761488148 cites W2083073031 @default.
• W2761488148 cites W2087172868 @default.
• W2761488148 cites W2093158866 @default.
• W2761488148 cites W2103796352 @default.
• W2761488148 cites W2105235256 @default.
• W2761488148 cites W2115351357 @default.
• W2761488148 cites W2118152564 @default.
• W2761488148 cites W2121743767 @default.
• W2761488148 cites W2123633897 @default.
• W2761488148 cites W2127559749 @default.
• W2761488148 cites W2127632164 @default.
• W2761488148 cites W2129148152 @default.
• W2761488148 cites W2143057570 @default.
• W2761488148 cites W2149055075 @default.
• W2761488148 cites W2154558042 @default.
• W2761488148 cites W2161021913 @default.
• W2761488148 cites W2287857102 @default.
• W2761488148 cites W2294536664 @default.
• W2761488148 cites W2339658711 @default.
• W2761488148 cites W2345645288 @default.
• W2761488148 cites W2418937816 @default.
• W2761488148 cites W2464767722 @default.
• W2761488148 cites W2464963697 @default.
• W2761488148 cites W2492884322 @default.
• W2761488148 cites W2511028559 @default.
• W2761488148 cites W2511586498 @default.
• W2761488148 cites W2529276663 @default.
• W2761488148 cites W2531856938 @default.
• W2761488148 cites W2560056817 @default.
• W2761488148 cites W2567208701 @default.
• W2761488148 cites W2570291199 @default.
• W2761488148 cites W2591871775 @default.
• W2761488148 doi "https://doi.org/10.1080/10245332.2017.1385192" @default.
• W2761488148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29022420" @default.
• W2761488148 hasPublicationYear "2017" @default.
• W2761488148 type Work @default.
• W2761488148 sameAs 2761488148 @default.
• W2761488148 citedByCount "2" @default.
• W2761488148 countsByYear W27614881482021 @default.
• W2761488148 countsByYear W27614881482022 @default.
• W2761488148 crossrefType "journal-article" @default.
• W2761488148 hasAuthorship W2761488148A5036582191 @default.
• W2761488148 hasAuthorship W2761488148A5037134717 @default.
• W2761488148 hasAuthorship W2761488148A5057335043 @default.
• W2761488148 hasAuthorship W2761488148A5091536542 @default.
• W2761488148 hasBestOaLocation W27614881481 @default.
• W2761488148 hasConcept C126322002 @default.
• W2761488148 hasConcept C160735492 @default.
• W2761488148 hasConcept C162324750 @default.
• W2761488148 hasConcept C177713679 @default.
• W2761488148 hasConcept C2776112149 @default.
• W2761488148 hasConcept C2779134260 @default.
• W2761488148 hasConcept C2779703844 @default.
• W2761488148 hasConcept C2780007613 @default.
• W2761488148 hasConcept C2780076729 @default.
• W2761488148 hasConcept C50522688 @default.
• W2761488148 hasConcept C71924100 @default.
• W2761488148 hasConceptScore W2761488148C126322002 @default.
• W2761488148 hasConceptScore W2761488148C160735492 @default.
• W2761488148 hasConceptScore W2761488148C162324750 @default.
• W2761488148 hasConceptScore W2761488148C177713679 @default.
• W2761488148 hasConceptScore W2761488148C2776112149 @default.
• W2761488148 hasConceptScore W2761488148C2779134260 @default.
• W2761488148 hasConceptScore W2761488148C2779703844 @default.
• W2761488148 hasConceptScore W2761488148C2780007613 @default.
• W2761488148 hasConceptScore W2761488148C2780076729 @default.
• W2761488148 hasConceptScore W2761488148C50522688 @default.
• W2761488148 hasConceptScore W2761488148C71924100 @default.
• W2761488148 hasIssue "4" @default.
• W2761488148 hasLocation W27614881481 @default.
• W2761488148 hasLocation W27614881482 @default.
• W2761488148 hasOpenAccess W2761488148 @default.
• W2761488148 hasPrimaryLocation W27614881481 @default.

• next